Background-Cystic fibrosis related diabetes (CFRD) has become increasingly common with the increasing longevity of patients with cystic fibrosis. The diagnosis of CFRD is important as its development may lead to a clinical deterioration which may be reversed with treatment. The oral glucose tolerance test (OGTT) is the method of choice in the diagnosis of CFRD, but performing OGTTs on all patients is inconvenient for patients and labour intensive for staV. The aim of this study was to identify a more selective approach in performing OGTTs in the diagnosis of CFRD based on the use of a combination of clinical and biochemical criteria. Methods-Clinically stable adult patients with cystic fibrosis not known to be diabetic attending the Royal Brompton Hospital Cystic Fibrosis Clinic for their annual review were invited to return within a month to have an OGTT. The result of the OGTT was compared with the results of tests performed during the annual review. The sensitivities and specificities of various methods used in the screening or diagnosis of CFRD were determined using OGTT as the "gold standard" diagnostic method. The combination of clinical and biochemical criteria which resulted in the highest sensitivity and specificity in the diagnosis of CFRD was determined. Results-Between August 1996 and May 1997 122 patients became eligible for the study, 91 of whom agreed to take part. The number of patients with normal, impaired, and diabetic glucose tolerance was 58 (64%), 21 (23%), and 12 (13%), respectively. When used alone, abnormal glycosylated haemoglobin (HbA1c) was found to have the highest sensitivity (83%; 95% CI 62 to 100) in the diagnosis of CFRD. The combination of an abnormal random blood glucose and/or abnormal HbA1c and/or symptoms of hyperglycaemia or weight loss was found to have the highest sensitivity (92%; 95% CI 76 to 100) in the diagnosis of CFRD. The specificity of this combination in the diagnosis of CFRD was 79% (95% CI 70 to 88). By selectively performing OGTTs in patients with one or more of the criteria cited above, 11 of the 12 patients with OGTT defined diabetes would have been identified.
Conclusions-Patients with cystic fibrosis already have to undergo a large number of routine investigations. The selective approach in performing OGTTs described here has the potential to identify the majority of patients with CFRD without the need to perform this investigation on all patients. This approach is likely to be welcomed by patients and will lead to significant savings in terms of time and resources for patients and staV. Further larger studies are warranted to validate this selective approach in the diagnosis of CFRD. (Thorax 1999; 54:40-43) Keywords: cystic fibrosis; diabetes mellitus; glucose tolerance test Cystic fibrosis related diabetes (CFRD) is a well recognised complication in patients with cystic fibrosis and the prevalence of this complication increases with age. 1 2 The diagnosis of CFRD is important as its development may be associated with clinical deterioration 3 4 which can be reversed by prompt treatment. 4 Various methods when used alone-including random blood glucose (RBG), fasting blood glucose (FBG), glycosylated haemoglobin (HbA1c), and symptoms of hyperglycaemiahave not been found to be suYciently sensitive or specific in the diagnosis of CFRD. 5 6 A two hour oral glucose tolerance test (OGTT) is generally regarded as the "gold standard" in the diagnosis of diabetes but performing OGTTs is time and resource consuming for both patients and staV. However, in the absence of any other standardised and practical diagnostic test, OGTT remains the method of choice in the diagnosis of CFRD. It has been suggested that all patients aged 10 or above with cystic fibrosis should have this test periodically. 5 The aim of the study was to identify a more selective approach in performing OGTT in the diagnosis of CFRD, based on the use of a combination of clinical and biochemical criteria. The sensitivities and specificities of various clinical and biochemical criteria, when used alone, in the diagnosis of CFRD would also be determined using OGTT as the "gold standard".
Methods
Adult patients (aged 16 or above) with cystic fibrosis not known to be diabetic who attended the Royal Brompton Hospital Adult Cystic Fibrosis Clinic for their annual review between August l996 and May l997 were invited to take part in the study. Patients with pulmonary exacerbations requiring oral or intravenous antibiotic therapy, recent (within six weeks) increase or change in systemic steroid dosage, recent commencement of enteral feeding, and pregnant patients were excluded. Cystic fibrosis was diagnosed by positive sweat tests with typical clinical findings, with or without genotype confirmation.
Each eligible patient was invited to take part in this study during the annual review visit. For those patients who agreed to take part, the following information was collected: RBG (patients with RBG >11.0 mmol/l are regarded as diabetic by the WHO criteria 7 ), HbA1c (normal <6.2%), the presence of symptoms of hyperglycaemia, unexplained weight loss (>5% of weight loss since previous visit), the presence of glycosuria.
Each patient was then invited to return to the clinic within one month in order to have a two hour OGTT performed. After an overnight fast the patient was asked to drink a solution containing 1.75 g/kg body weight (maximum 75 g) of glucose BP dissolved in 250 ml of water within 2-3 minutes. Blood samples were taken just before and two hours after ingestion of the glucose solution. Patients' glucose tolerance status was classified according to the WHO criteria into normal, impaired, or diabetic glucose tolerance (two hour venous plasma glucose <7.8 mmol/l, 7.8-11.0 mmol/l, >11.0 mmol/l, respectively). The same calculations were then made to determine the sensitivities and specificities of using various combinations of clinical and biochemical criteria described above in the diagnosis of CFRD. Three cut oV values for RBG (6, 8.5 and 11 mmol/l) were chosen. According to the WHO criteria, 7 diabetes is "likely" in patients with RBG above 11 mmol/l and "unlikely" if RBG is 6 mmol/l or below; 8.5 mmol/l represents the mid point of these two values. The combination of criteria which resulted in the highest sensitivity and specificity was then determined.
Blood samples for plasma glucose were collected in fluoride oxalate tubes and venous plasma glucose was determined by an oxygen rate method using a Beckman CX 7 Delta analyser (Beckman Instruments, USA). Blood samples for the determination of HbA1c were collected in EDTA-containing tubes and HbA1c was determined by an ion capture assay using an Abbott IMX analyser (Abbott Laboratories, USA). The presence of glycosuria was determined by Multistix (Bayer Diagnostics, UK).
The study was approved by the local ethics committee and written consents were obtained from all patients who participated.
Results
A total of 518 patients with cystic fibrosis of median age 26 (range 16-60) attended the Royal Brompton Hospital Cystic Fibrosis Clinic in August 1996 of whom 74 patients Inability to travel to the hospital in the morning due to work commitments or long distance to travel were the usual reasons for the patients' inability to take part in the study. The demographic details and the results of the OGTTs of the 91 patients studied is shown in table 1. The mean age and body mass index were not significantly diVerent between those who took part in the study and those who were unable to do so. The sensitivities and specificities of individual clinical and biochemical criteria alone in the diagnosis of CFRD, using OGTT as the "gold standard" diagnostic method for CFRD, is shown in table 2. An abnormal HbA1c was found to have the highest sensitivity (83%; 95% CI 62 to 100) when used alone in the diagnosis of CFRD. By combining the use of diVerent diagnostic criteria, the sensitivity in the diagnosis of CFRD could be increased further (table 3) . The highest sensitivity achieved was 92% (95% CI 76 to 100) in patients who had either abnormal RBG (>11.0 mmol/l) and/or abnormal HbA1c (>6.1%) and/or the presence of symptoms of hyperglycaemia or unexplained weight loss. The presence of glycosuria did not increase the sensitivity further. This higher sensitivity was achieved at the expense of a lower specificity of 79% (95% CI 70 to 88) so some patients with one or more of the abnormal criteria cited above may not have CFRD. By selectively performing OGTTs only in this group of patients with one or more of the abnormal criteria cited above, those patients within the group with true CFRD would have been identified and those without CFRD within the group would have been excluded. If such a selective approach was used for the 91 patients studied, only 28 (31%; 95% CI 21 to 41) of the 91 patients would have to undergo an OGTT, but 11 of the 12 patients (92%, 95% CI 76 to 100) with OGTT defined diabetes within the group would have been identified. The twelfth patient had a normal RBG, HbA1c and was asymptomatic and would not have been identified unless an OGTT was performed.
Discussion
Various methods, including OGTT, have been used at diVerent cystic fibrosis centres for the screening and diagnosis of CFRD. At the authors' unit patients with cystic fibrosis have been screened for diabetes at least annually using RBG and HbA1c for some years. In this study we found that an abnormal RBG (>11.0 mmol/l), when used alone, has a poor sensitivity in the diagnosis of CFRD. In common with the study by Lanng and colleagues, 5 we also found that an abnormal FBG and the presence of symptoms of hyperglycaemia when used alone have poor sensitivity in the diagnosis of CFRD. Lanng and colleagues reported that only 16% of their patients with OGTT defined diabetes had abnormal HbA1c. This is in contrast to 83% (95% CI 62 to 100) of our diabetic patients with abnormal HbA1c values. In the Danish study, ion exchange chromatography was used to measure HbA1c and a higher reference range was used (upper limit 6.4%). These diVerences are insuYcient to explain the large diVerences in the sensitivities between the two studies. HbA1c is a specific type of glycated haemoglobin formed by the reaction of glucose with the N-terminal amino group of the haemoglobin beta chain. It provides an integrated measure of past glucose levels and would be expected to be increased in patients with diabetes. 8 We are unable to explain the low percentage of OGTT defined diabetics with abnormal HbA1c levels in the Danish cystic fibrosis patient group. Although the presence of glycosuria has a high specificity in the diagnosis of CFRD, this test is too insensitive to be used as a diagnostic or screening test for the condition. Our study therefore provides further evidence that methods other than OGTT, when used alone, are not suYciently sensitive or specific in the diagnosis of CFRD. However, performing an OGTT on all patients is very inconvenient for the patients and labour intensive for staV. The need to have an OGTT performed regularly may in some cases decrease patients' compliance with clinic visits.
In this study we have shown that a selective approach in performing OGTTs has the *Selective approach = performing OGTTs only in patients with one or more of the abnormal criteria (marked 'Yes') cited above. **The presence of an abnormal RBG (>11.0 mmol/l) and/or an abnormal HbA1c (>6.1%) and/or the presence of symptoms of hyperglycaemia or unexplained weight loss has the highest sensitivity and specificity in the diagnosis of CFRD. Including the presence of glycosuria did not increase these values further.
